ReviewJournal of experimental pharmacology2018
Propranolol for the treatment of vascular sarcomas.
Review in Journal of experimental pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 44 citations in OpenAlex.
- Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker.Pharmacology research & perspectives · 2026Article
- Primary Hepatic Hemangiosarcoma With Hemoperitoneum in a Dog: Clinical Course and Therapeutic Outcome.Case reports in veterinary medicine · 2026Article
- Vaccination Against Extracellular Vimentin Plus Doxorubicin for Canine Hemangiosarcoma.International journal of molecular sciences · 2025Article
- Plasminogen Activator Inhibitor-1 in Skin Malignancies: Therapeutic Implications of Its Inhibition.Biomolecules · 2025Review
- Retrospective Study Evaluating Outcomes Following Palliative Radiotherapy With or Without Chemotherapy for Dogs With Presumed Cardiac Hemangiosarcoma.Veterinary and comparative oncology · 2025Article
- Stress regulatory hormones and cancer: the contribution of epinephrine and cancer therapeutic value of beta blockers.Endocrine · 2025Review
- Old drugs, new challenges: reassigning drugs for cancer therapies.Cellular & molecular biology letters · 2025Review
- Congenital Vascular and Lymphatic Diseases.Circulation research · 2024Review
- Radiation-induced angiosarcoma of the breast: retrospective analysis at a regional treatment centre.Breast cancer (Tokyo, Japan) · 2024Article
- Adrenoceptors: Receptors, Ligands and Their Clinical Uses, Molecular Pharmacology and Assays.Handbook of experimental pharmacology · 2024Review
- The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive.International journal of molecular sciences · 2023Review
- Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck Cancer.JCO precision oncology · 2023Article
- Efficacy and adverse events of anthracycline and propranolol combination in five dogs with stage 3 hemangiosarcoma.Open veterinary journal · 2023Article
- Review
- Primary angiosarcoma of the breast in an early adolescent female.BMJ case reports · 2023Article
- Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems.Current oncology (Toronto, Ont.) · 2023Review
- Repurposing Drugs in Small Animal Oncology.Animals : an open access journal from MDPI · 2022Review
- Medical management of vascular anomalies of the head and neck.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2022Review
- Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy.Medicina (Kaunas, Lithuania) · 2022Review
- Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups.Immunologic research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular sarcomas are abnormal proliferations of endothelial cells. They range from benign hemangioma to aggressive angiosarcoma, and are characterized by dysregulated angiogenic signaling. Propranolol is a β-adrenergic receptor inhibitor that has demonstrated clinical efficacy in benign infantile hemangioma, and is now being used experimentally for more aggressive vascular sarcomas and other cancers. In this review, we discuss the use of propranolol in targeting these receptors in vascular tumors and other cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.